● Pharmacologically Solved
Active compound isolated, mechanism characterized, now a regulated drug or claim.
The Solution
The solved cases: where Ayurveda became pharmacology
Most of Ayurveda is still being translated. This page covers the part that already has been: compounds where a 3,000-year-old use and a modern mechanism now describe the same molecule. We include one entry that failed replication, on purpose. A translation project with no failures is not being honest about its method.
Evidence-tier key
Four tiers, eleven cases
Every case carries one tier. The chart shows how the eleven entries divide.
● RCT / Meta-Analysis Validated
Multiple randomized trials or a pooled meta-analysis, consistent direction of effect.
● Single RCT / Limited N
Real trial data, but a small sample or not yet replicated.
▲ Acknowledged Gap
Trialed rigorously, and the traditional claim did not hold up.
01
Sarpagandha
Pharmacologically SolvedRauwolfia serpentina → Reserpine
- Traditional use
- Used in classical Ayurveda for insomnia, agitation and "insanity", and for snakebite.
- What modern science found
- Reserpine was isolated in 1952 (Ciba). It irreversibly blocks VMAT2, the vesicular monoamine transporter, depleting presynaptic norepinephrine, dopamine and serotonin.
- Clinical outcome
- One of the first modern antihypertensives and antipsychotics. Used for decades, then largely replaced by drugs with fewer depressive side effects.
- Biohacking relevance
- Not a biohack. A cautionary anchor. It shows mechanism isolation works, and it is why "natural means no CNS side effects" is false: reserpine can cause clinical depression at therapeutic doses. Validated is not the same as risk-free.
02
Sadabahar
Pharmacologically SolvedCatharanthus roseus → Vincristine & Vinblastine
- Traditional use
- Periwinkle, used in Ayurvedic and regional folk medicine for diabetes.
- What modern science found
- Screening for an oral antidiabetic effect (never confirmed) turned up potent anti-leukemic activity instead. The vinca alkaloids bind tubulin and block microtubule polymerization, arresting cells in mitosis.
- Clinical outcome
- Vincristine and vinblastine are WHO Essential Medicines, first-line today in pediatric acute lymphoblastic leukemia and Hodgkin lymphoma.
- Biohacking relevance
- The clearest proof that an Ayurvedic plant can yield a frontline drug. A credibility case, not a wellness protocol.
03
Haridra
RCT / Meta-Analysis ValidatedCurcuma longa + Piperine → Curcumin
- Traditional use
- Used for inflammation, wound healing and joint pain, and paired with black pepper centuries before anyone knew why.
- The mechanism behind the pairing
- Shoba et al., Planta Medica 1998: piperine raised curcumin bioavailability by 154% in rats and 2000% in human volunteers, by inhibiting glucuronidation and P-glycoprotein efflux.
- Clinical outcome
- A 2021 meta-analysis in Complementary Therapies in Medicine pooled 11 RCTs and 1,258 knee osteoarthritis patients. Curcuminoids beat comparators on VAS and WOMAC pain scores, with no dose-response difference between ≥1000 mg/day and lower doses, and fewer adverse events than NSAIDs.
- Protocol rule
- Never supplement curcumin without piperine or a lipidated or phytosome formulation. Without it, you are taking a near-inert compound.
04
Kapikacchu
Single RCT / Limited NMucuna pruriens → Natural L-DOPA
- Traditional use
- A Rasayana (rejuvenative) herb for tremor and vitality.
- What modern science found
- Mucuna seeds naturally contain levodopa, the dopamine precursor used in Parkinson's treatment.
- Clinical outcome
- Katzenschlager et al., J Neurol Neurosurg Psychiatry 2004;75(12):1672–1677. Double-blind crossover trial in 8 Parkinson's patients: 30 g mucuna gave faster onset (34.6 vs 68.5 min, p=0.021), 110% higher peak plasma levodopa and 21.9% longer "on" time than levodopa/carbidopa.
- Biohacking relevance
- Striking data, but n=8 and never replicated at scale. This is a prescription question for diagnosed patients and sits outside a wellness platform. Evidence of mechanism only. Do not self-administer.
05
Ashwagandha
RCT / Meta-Analysis ValidatedWithania somnifera → Cortisol & stress reactivity
- Traditional use
- The signature Rasayana adaptogen for vitality and resilience to stress.
- Clinical outcome
- Chandrasekhar, Kapoor & Anishetty, Indian J Psychol Med, Jan 2012. Randomized, double-blind, placebo-controlled: standardized root extract 300 mg twice daily for 60 days in adults with chronic stress lowered serum cortisol and validated stress scores versus placebo.
- Protocol application
- One of the most defensible daily entries: standardized root-extract dosing, a named biomarker (cortisol) and a fixed 60-day window you can mirror.
06
Methi
RCT / Meta-Analysis ValidatedTrigonella foenum-graecum → Glycemic control
- Traditional use
- A classical food-medicine for prameha, conditions resembling diabetes.
- Clinical outcome
- Several recent meta-analyses of RCTs in type 2 diabetes and prediabetes show fenugreek lowers fasting glucose and HbA1c as an adjunct to standard therapy.
- Protocol application
- Adjunct only, for metabolic-phenotype users. Always alongside, never instead of, prescribed glucose-lowering therapy.
07
Shallaki
RCT / Meta-Analysis Validated · with an honest caveatBoswellia serrata → Joint inflammation
- Traditional use
- An anti-inflammatory resin for joint and connective-tissue complaints.
- Clinical outcome
- A 2020 meta-analysis found Boswellia extracts reduced osteoarthritis pain versus placebo. The Cochrane review CD002947 points the same way but rates evidence quality low to moderate, citing small trials and industry funding.
- Protocol application
- Pairs with curcumin and piperine in an anti-inflammatory stack. The Cochrane caveat stays visible. Do not round this up.
08
Brahmi
RCT / Meta-Analysis ValidatedBacopa monnieri → Cognitive performance
- Traditional use
- A Medhya Rasayana, the classical cognition herb.
- Clinical outcome
- Pase et al., J Altern Complement Med 2012, systematic review of RCTs: chronic dosing over weeks to months consistently improved delayed free recall. No reliable effect on working memory or reaction time.
- Protocol application
- A fair nootropic entry. Effects take weeks and are specific to memory consolidation. It is not an acute stimulant.
09
Isabgol
Pharmacologically Solved · regulatory-gradePlantago ovata → Cholesterol
- Traditional use
- A classical bulk laxative and gut-soothing fiber.
- Clinical outcome
- Psyllium soluble fiber has carried an FDA-approved health claim since 1998 for reducing coronary heart disease risk through LDL lowering, backed by a large RCT and meta-analysis base.
- Protocol application
- The highest-confidence, lowest-risk entry. Boring but bulletproof, and the one to show a skeptical physician.
10
Gurmar
Single RCT / Limited NGymnema sylvestre → Adjunct glycemic support
- Traditional use
- "Sugar destroyer", chewed to blunt sweet taste.
- Clinical outcome
- Registered trials and older controlled studies show glucose lowering in type 2 diabetes, including a comparison against metformin. Gymnemic acids blocking glucose absorption and sweet receptors is plausible. Beta-cell regeneration remains unproven.
- Protocol application
- Promising but early. Pair with fenugreek and flag the beta-cell claim as unproven.
11
Guggulu
Acknowledged GapCommiphora mukul → Cholesterol
- Traditional use
- A classical lipid-lowering resin, still one of the most cited "Ayurvedic statin" claims.
- What the rigorous trial found
- Szapary et al., Arch Intern Med 2003: in a randomized, placebo-controlled trial, guggulipid did not lower LDL cholesterol, and the higher dose was linked to a modest LDL increase.
- Clinical outcome
- The traditional claim did not hold up under a controlled trial in a Western population.
- Why it stays on the page
- This is our test of honesty. Citing guggulu as solved while leaving out this trial would be marketing, not science. A skeptical scientist will look for it first.
Knowing what works is half of it. The other half is how to use it safely.
See the process